Real-world evidence on fremanezumab for migraine treatment in Japan: a retrospective analysis

被引：0
|
作者：
Takizawa, T. [1 ]
Ohtani, S. [1 ,2 ]
Watanabe, N. [1 ]
Ihara, K. [1 ]
Takahashi, N. [1 ]
Miyazaki, N. [3 ]
Ishizuchi, K. [1 ]
Takemura, R. [3 ]
Hori, S. [2 ]
Nakahara, J. [1 ]
机构：
[1] Keio Univ, Sch Med, Dept Neurol, Tokyo, Japan
[2] Keio Univ, Fac Pharm, Div Drug Informat, Tokyo, Japan
[3] Keio Univ Hosp, Biostat Unit, Clin & Translat Res Ctr, Tokyo, Japan
来源：
JOURNAL OF HEADACHE AND PAIN | 2024年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P254
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Real-World Evidence of the Safety and Effectiveness of Atogepant Added to OnabotulinumtoxinA for the Preventive Treatment of Chronic Migraine: A Retrospective Chart Review
    Blumenfeld, Andrew M.
    Mechtler, Laszlo
    Cook, Lisa
    Rhyne, Christopher
    Jenkins, Brian
    Hughes, Olivia
    Dabruzzo, Brett
    Manack Adams, Aubrey
    Diamond, Merle
    PAIN AND THERAPY, 2024, 13 (06) : 1571 - 1587
  • [42] PEARL study protocol: a real-world study of fremanezumab effectiveness in patients with chronic or episodic migraine
    Ashina, Messoud
    Amin, Faisal Mohammad
    Kokturk, Pinar
    Cohen, Joshua M.
    Konings, Martijn
    Tassorelli, Cristina
    Lyras, Leonidas
    Mitsikostas, Dimos-Dimitrios
    PAIN MANAGEMENT, 2021, 11 (06) : 647 - 654
  • [43] Real-world effectiveness of fremanezumab for the preventive treatment of migraine: Interim analysis of the pan-European, prospective, observational, phase 4 PEARL study
    Ashina, Messoud
    Mitsikostas, Dimos D.
    Amin, Faisal Mohammad
    Kokturk, Pinar
    Schankin, Christoph J.
    Sahin, Gurdal
    Pozo-Rosich, Patricia
    Dorman, Paul J.
    Nezadal, Tomas
    Poole, Anne Christine
    Martins, Isabel Pavao
    Sumelahti, Marja-Liisa
    Campos, Verena Ramirez
    Ahn, Andrew H.
    Lyras, Leonidas
    Tassorelli, Cristina
    CEPHALALGIA, 2023, 43 (11)
  • [44] Retrospective Real-World Evaluation Of Erenumab In Refractory Chronic Migraine
    Ong, Hui Ching
    Ghadiri-Sani, Mona
    CEPHALALGIA, 2023, 43 (1supp)
  • [45] REAL-WORLD EFFECTIVENESS OF FREMANEZUMAB TREATMENT FOR REDUCING MONTHLY MIGRAINE AND HEADACHE DAYS IN US PATIENTS HAVING DIFFERENT NUMBERS OF PRIOR MIGRAINE PREVENTIVE TREATMENT FAILURES
    Cohen, J.
    Thompson, S.
    Sun, R.
    Driessen, M.
    Seminerio, M.
    Carr, K.
    Mu, F.
    VALUE IN HEALTH, 2022, 25 (01) : S30 - S30
  • [46] Real-world effectiveness and tolerability of fremanezumab for the preventive treatment of migraine in patients using concomitant gepants for acute treatment in a US neurology practice
    Eugeni, P.
    HEADACHE, 2022, 62 (07): : 927 - 927
  • [47] THE IMPACT OF USING REAL-WORLD DATA ON THE COST-EFFECTIVENESS OF FREMANEZUMAB FOR MIGRAINE PREVENTION IN A UK HEALTHCARE PERSPECTIVE ANALYSIS
    Sacco, S.
    Freddi, M.
    Edwards, J.
    Akcicek, H.
    Driessen, M.
    VALUE IN HEALTH, 2023, 26 (12) : S118 - S118
  • [48] US Real-world Effectiveness of Quarterly and Monthly Fremanezumab for Reducing Migraine Days and Headache Days in Adult Patients With Migraine
    Cohen, Joshua M.
    Thompson, Stephen
    Ayyagari, Rajeev
    Driessen, Maurice
    Seminerio, Michael
    Carr, Karen
    Yim, Erica
    NEUROLOGY, 2021, 96 (15)
  • [49] Real-world evidence on the economic implications of CGRP-mAbs as preventive treatment of migraine
    Siersbaek, Nikolaj
    Kilsdal, Laerke
    Jervelund, Christian
    Antic, Sonja
    Bendtsen, Lars
    CEPHALALGIA, 2022, 42 (1_SUPPL) : 1 - 2
  • [50] Real-world evidence on the economic implications of CGRP-mAbs as preventive treatment of migraine
    Nikolaj Siersbæk
    Lærke Kilsdal
    Christian Jervelund
    Sonja Antic
    Lars Bendtsen
    BMC Neurology, 23
12345